SIDNEY KIMMEL CANCER CENTER at Johns Hopkins University made several personnel changes.
CITY OF HOPE announced several appointments to its faculty.
STUART ORKIN received Boston Children's Hospital's Lifetime Impact Award at the hospital's third annual Global Pediatric Innovation Summit.
A group of 42 organizations sent an open letter to a congressional committee urging them to consider the important role of the FDA in the regulation of laboratory-developed tests.
Rep. Mike Fitzpatrick accused top leaders of Brigham & Women's Hospital of retaliating against patient advocates Amy Reed and Hooman Noorchashm when a hospital administrator declared the couple a security threat and subjected them to a physical search.
What does it say about our national commitment to research integrity that the Department of Health and Human Services' Office of Research Integrity has concluded that a five-year ban on federal research funding for one individual researcher is a sufficient response to a case involving millions of taxpayer dollars, completely fabricated data, and hundreds to thousands of patients in invasive clinical trials?
After a five-year investigation, the HHS Office of Research Integrity announced that it has settled with former Duke University researcher Anil Potti.
MD Anderson Cancer Center entered into a collaboration with CytomX Therapeutics to research Probody-enabled chimeric antigen receptor natural killer cell therapies, to be known as ProCAR-NK cell therapies. MD Anderson will develop allogeneic umbilical cord blood and peripheral blood derived NK-cell therapies and combine it with CytomX’s Probody technology to address new targets for this […]
FDA granted Breakthrough Therapy Designation to pexidartinib (formerly PLX3397) for the treatment of tenosynovial giant cell tumor where surgical removal of the tumor would be associated with potentially worsening functional limitation or severe morbidity. Currently, there is no FDA-approved systemic therapy for the treatment of TGCT. The designation was granted based on results from an […]
Researchers from The Cancer Genome Atlas Network recently published two studies—one identifying seven distinct molecular subtypes of prostate cancer, and one exploring the genetic drivers of papillary renal cell carcinoma.
